- Home
- DXC vs ACAD Comparison
DXC vs ACAD Comparison
Compare DXC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- ACAD
- Stock Information
- Founded
- DXC 1959
- ACAD 1993
- Country
- DXC United States
- ACAD United States
- Employees
- DXC N/A
- ACAD N/A
- Industry
- DXC EDP Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- ACAD Health Care
- Exchange
- DXC Nasdaq
- ACAD Nasdaq
- Market Cap
- DXC 3.5B
- ACAD 3.4B
- IPO Year
- DXC N/A
- ACAD 2004
- Fundamental
- Price
- DXC $19.56
- ACAD $19.95
- Analyst Decision
- DXC Hold
- ACAD Buy
- Analyst Count
- DXC 8
- ACAD 19
- Target Price
- DXC $21.38
- ACAD $25.33
- AVG Volume (30 Days)
- DXC 1.1M
- ACAD 1.6M
- Earning Date
- DXC 02-04-2025
- ACAD 02-26-2025
- Dividend Yield
- DXC N/A
- ACAD N/A
- EPS Growth
- DXC N/A
- ACAD N/A
- EPS
- DXC N/A
- ACAD 0.78
- Revenue
- DXC $13,088,000,000.00
- ACAD $929,236,000.00
- Revenue This Year
- DXC N/A
- ACAD $36.88
- Revenue Next Year
- DXC N/A
- ACAD $8.01
- P/E Ratio
- DXC N/A
- ACAD $25.70
- Revenue Growth
- DXC N/A
- ACAD 47.06
- 52 Week Low
- DXC $14.79
- ACAD $14.15
- 52 Week High
- DXC $24.83
- ACAD $26.56
- Technical
- Relative Strength Index (RSI)
- DXC 39.15
- ACAD 60.25
- Support Level
- DXC $19.69
- ACAD $19.52
- Resistance Level
- DXC $21.35
- ACAD $20.29
- Average True Range (ATR)
- DXC 0.97
- ACAD 0.68
- MACD
- DXC -0.17
- ACAD 0.08
- Stochastic Oscillator
- DXC 1.87
- ACAD 72.62
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.